Has William Penny received payments from drug or device companies?

Yes. Drug and device makers reported $991 in general payments to William Penny across 11 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean William Penny did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about William Penny come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

William Penny

Cardiovascular Disease · San Diego, CANPI 1700970498

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Medtronic accounts for 62.7% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $347 and has fallen 66.9% since, to $115 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in CA, where the typical reported total is $2,142.

$991in general payments, 2019–2025

Across 11 payments — averaging $90.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$621
Veryan Medical Incorporated$136
Abiomed$126
Biotronik Inc.$57
Abbott$50

$829,358in research payments, 2019–2025

Across 141 payments — averaging $5881.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Amgen$381K
CSL Behring$195K
American Regent$133K
AbbVie$84K
Janssen Research & Development, LLC$34K
E.r. Squibb & Sons, L.L.C.$2K

What the payments were for

Food & beverage$991100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic	4	$621
Veryan Medical Incorporated	1	$136
Abiomed	1	$126
Biotronik Inc.	3	$57
Abbott	2	$50

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$991 in reported general payments places this provider in the 35th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California →

Other cardiovascular disease in San Diego

Lori DanielsSan Diego$278K
Michael WilkinsonSan Diego$145K
Ted LoveHillsborough$102.8M
Paul KurthSanta Barbara$6.1M
Jason RogersSacramento$4.4M
Matthew BudoffTorrance$3.6M
Eric Topolla Jolla$2.2M
Cathleen Bairey-MerzLos Angeles$1.2M
Gagan SinghSacramento$1.2M
Pam Taubla Jolla$1.2M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →